Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program
2025 · 2nd Quarter (Apr 1 - June 30)
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
Filed by E3 STRATEGIC CONSULTING GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 1, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- E3 STRATEGIC CONSULTING GROUP
- Filing UUID
- f0f4bac9-f255-48cb-a50f-0a9666ec0ff5
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.